A Phase 1a/1b Dose Escalation/Expansion Study of the Anti-PD-1 Monoclonal Antibody Nofazinlimab in Chinese Patients with Solid Tumors or Lymphoma

Background Immune checkpoint blockade with anti-programmed cell death 1 (PD-1) antibodies has demonstrated efficacy in multiple tumor types. Nofazinlimab is a humanized rat antibody targeting PD-1. A first-in-human study of nofazinlimab conducted in Australia found no dose-limiting toxicities (DLTs)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Targeted oncology 2024-09, Vol.19 (5), p.723-733
Hauptverfasser:	Gong, Jifang, Guo, Ye, Zhang, Yanqiao, Ba, Yi, Chen, Tong, Li, Wei, Zhou, Caicun, Wang, Mengzhao, Yang, Haiyan, Zhou, Yuhong, Cai, Qiqing, Wang, Ziping, Huang, Gang, Zhang, Wei, Su, Rila, Cai, Zhongheng, Yue, Zenglian, Dou, Jinzhou, Li, Peiqi, Wu, Rachel, Tse, Archie N., Shen, Lin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antibodies, Monoclonal, Humanized - pharmacology Antibodies, Monoclonal, Humanized - therapeutic use Biomedicine Cancer therapies Cell death China Combination therapy Drug dosages East Asian People Female Humans Investigations Liver cancer Lymphoma Lymphoma - drug therapy Male Maximum Tolerated Dose Medicine Medicine & Public Health Middle Aged Monoclonal antibodies NCT NCT03809767 Neoplasms - drug therapy Nervous system Oncology Original Research Article Programmed Cell Death 1 Receptor - antagonists & inhibitors Tumors Vascular endothelial growth factor
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!